Annual report [Section 13 and 15(d), not S-K Item 405]

Commitments and Contingencies (Details)

v3.26.1
Commitments and Contingencies (Details)
£ in Millions, shares in Millions
 12 Months Ended
Nov. 23, 2025
USD ($)
shares
May 31, 2026
USD ($)
Item
May 31, 2025
USD ($)
May 31, 2026
GBP (£)
Commitments and Contingencies        
Operating lease costs   $ 100,000 $ 100,000  
Estimated Litigation Liability, Current $ 15,400,000 $ 15,347,000 $ 0  
Class action lawsuit - settlement payable in cash $ 500,000      
Class action lawsuit - settlement payable in shares | shares 49      
Side Letter Agreement With Samsung        
Commitments and Contingencies        
Contractual obligation, percentage of qualifying revenue agreed to pay   20.00%    
Amount of contractual obligation included in other liabilities   $ 43,600,000    
Progenics Purchase Agreement        
Commitments and Contingencies        
Amount of milestone payments payable   $ 5,000,000    
Percentage of royalty payable   3.50%    
Amount payable upon filing BLA with FDA   $ 500,000    
Amount payable upon FDA approval   500,000    
Annual maintenance fees   $ 150,000    
Progenics Purchase Agreement | Royalty Payable in Initial 10 Years        
Commitments and Contingencies        
Percentage of royalty payable   5.00%    
Lonza Agreement        
Commitments and Contingencies        
Number of contract manufacturers | Item   2    
Annual license fee   $ 350,000   £ 0.3
Royalty on net sales (as a percent)   2.00%   2.00%